Heather J Smith-Adam

Summary

Publications

  1. ncbi Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
    Heather J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    J Antimicrob Chemother 49:893-5. 2002
  2. ncbi Stretching the mutant prevention concentration (MPC) beyond its limits
    Heather J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    J Antimicrob Chemother 51:1323-5. 2003
  3. pmc Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics
    H J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Antimicrob Agents Chemother 48:3630-5. 2004
  4. pmc Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates
    Heather J Smith
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba, R3A 1R9, Canada
    Antimicrob Agents Chemother 48:3954-8. 2004
  5. pmc Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants
    Heather J Smith-Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, R3A 1R9 Canada
    Antimicrob Agents Chemother 49:846-8. 2005

Detail Information

Publications5

  1. ncbi Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
    Heather J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    J Antimicrob Chemother 49:893-5. 2002
  2. ncbi Stretching the mutant prevention concentration (MPC) beyond its limits
    Heather J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    J Antimicrob Chemother 51:1323-5. 2003
  3. pmc Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics
    H J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Antimicrob Agents Chemother 48:3630-5. 2004
    ....
  4. pmc Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates
    Heather J Smith
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba, R3A 1R9, Canada
    Antimicrob Agents Chemother 48:3954-8. 2004
    ..However, once a ParC mutation is present, the MPC increases dramatically for all fluoroquinolones...
  5. pmc Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants
    Heather J Smith-Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, R3A 1R9 Canada
    Antimicrob Agents Chemother 49:846-8. 2005
    ..Fluoroquinolone resistance mechanisms, whether efflux or chromosomally mediated, remained stable in both clinical and laboratory-derived mutants...